P1, N=5, Terminated, Bristol-Myers Squibb | N=65 --> 5 | Trial completion date: Mar 2025 --> May 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> May 2023; Business objectives have changed.

10 months ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

cyclophosphamide • fludarabine IV • BMS-986403

1year

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)

P1, N=65, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | Trial completion date: Jan 2029 --> Mar 2025 | Trial primary completion date: Jan 2029 --> Mar 2025

1 year ago

Enrollment closed • Trial completion date • Trial primary completion date

cyclophosphamide • fludarabine IV • BMS-986403